[Veterinary and clinical experience of the use of a beta2-receptor-stimulating sympathicomimetic agent (NAB 365) in horses with respiratory discase (author's transl)].
The manufacturers state that NAB 365 is a beta2-receptor-stimulating sympathicomimetic agent. According to the medical literature it combines a bronchial antispasmodic effect with certain bronchia secretolytic properties and has few untoward side-effects on, for instance, the heart and intestine. The effectiveness of administration of NAB 365 in horses with chronic or acute respiratory disease was tested in the Department of Veterinary Internal medicine in Utrecht. NAB 365 administered at a dosage of 0.8 gamma/kg, of body weight was found to have a marked bronchodilative effect in horses. There was also evidence of a bronchialsecretolytic effect. NAB 365 has a beneficial effect on respiration. At a dosage of 0.8 gamma/kg of body weight, twice daily, there are few side-effects, even when administration is continued for a fortnight. The clinical effect on respiration continued practically throughout the day.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002976:Clenbuterol / Q000627:therapeutic use*; D004341:Drug Evaluation; D004983:Ethanolamines / Q000627:therapeutic use*; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D012119:Respiration / Q000187:drug effects; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000662:veterinary*
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; D002976:Clenbuterol
Enkele veterinair-klinische ervaringen met het gebruik van een beta2-receptoren stimulerend sympaticomymeticum (NAB 365) bij paarden met longaandoeningen.